) succeeded again in a patent related lawsuit brought by Applied
Medical Resources, Inc. against the company. In May 2011, Applied
Medical sued Covidien for selling some trocar products that
infringe its patent.
ADVAXIS INC (ADXS): Free Stock Analysis
ALERE INC (ALR): Free Stock Analysis Report
COVIDIEN PLC (COV): Free Stock Analysis
PLC SYSTEMS INC (PLCSF): Get Free Report
To read this article on Zacks.com click here.
On Aug 27, the United States Court of Appeals for the Federal
Circuit ruled in favor of Covidien, stating that its trocar
products do not infringe Applied Medical's patent, which is the
same as the previous lower court's ruling.
Since 2000, this is the fifth patent infringement lawsuit brought
by Applied Medical against COV relating to trocars seals.
However, Covidien received clean chits in all the cases.
Recently, Covidien opened its first research & development
(R&D) and training & education center in Korea that
covers an area of more than 6,000 square meters. The center known
as Covidien Center of Innovation Korea or CCI Korea intends to
raise awareness of various diseases and offer opportunities for
enhancing healthcare professionals' capabilities by providing
access to a full-range of COV's medical devices.
The facility entailed an investment of $21 million over a three
year period. It houses a surgical lab with 11 operating stations,
an intensive care unit (ICU) lab with two ICU stations and a
human patient simulator, and an auditorium with seating capacity
for 112 people.
Covidien posted flat adjusted earnings per share from continuing
operations of 91 cents for the third quarter of fiscal 2013, on a
year-over-year basis. However, earnings beat the Zacks Consensus
Estimate by a penny.
Revenues in the quarter increased 3% (up 5% in constant currency)
to $2,578 million, driven by higher sales in the Medical Devices
segment. Revenues were slightly below the Zacks Consensus
Estimate of $2,587 million.
On a geographic basis, revenues in the U.S. market decreased 3%
to $1,299 million while international revenues climbed 10% (up
14% in constant currency) to $1,279 million, driven by emerging
Currently, COV carries a Zacks Rank #3 (Hold). While we remain on
the sidelines regarding the company, other companies that are
performing well include
PLC Systems Inc.
), both with a Zacks Rank #1 (Strong Buy), and
) with a Zacks Rank #2 (Buy).